These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 20590906

  • 1. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
    Burak KW, Thomas MB, Zhu AX.
    HPB (Oxford); 2010 Jun; 12(5):321-2. PubMed ID: 20590906
    [No Abstract] [Full Text] [Related]

  • 2. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
    Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP, American Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, Society for Surgery of the Alimentary Tract.
    HPB (Oxford); 2010 Jun; 12(5):313-20. PubMed ID: 20590905
    [Abstract] [Full Text] [Related]

  • 3. Major achievements in hepatocellular carcinoma.
    Bruix J, Llovet JM.
    Lancet; 2009 Feb 21; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract] [Full Text] [Related]

  • 4. Review article: the management of hepatocellular carcinoma.
    Cabrera R, Nelson DR.
    Aliment Pharmacol Ther; 2010 Feb 15; 31(4):461-76. PubMed ID: 19925500
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
    Kim DY, Han KH.
    J Gastroenterol Hepatol; 2011 Nov 15; 26(11):1585-6. PubMed ID: 22011294
    [No Abstract] [Full Text] [Related]

  • 6. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
    Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E.
    Scand J Gastroenterol; 2010 Apr 15; 45(4):511-2. PubMed ID: 20113152
    [No Abstract] [Full Text] [Related]

  • 7. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF, Chapiro J.
    Clin Adv Hematol Oncol; 2016 Aug 15; 14(8):585-7. PubMed ID: 27487101
    [No Abstract] [Full Text] [Related]

  • 8. Current management of hepatocellular carcinoma.
    Mendizabal M, Reddy KR.
    Med Clin North Am; 2009 Jul 15; 93(4):885-900, viii. PubMed ID: 19577120
    [Abstract] [Full Text] [Related]

  • 9. Contemporary management of hepatocellular carcinoma.
    Palmer D.
    Clin Med (Lond); 2008 Aug 15; 8(4):442-7. PubMed ID: 18724617
    [No Abstract] [Full Text] [Related]

  • 10. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
    Di Maio M, Daniele B, Perrone F.
    Nat Rev Clin Oncol; 2009 Sep 15; 6(9):505-6. PubMed ID: 19707242
    [No Abstract] [Full Text] [Related]

  • 11. Sorafenib in hepatocellular carcinoma.
    Josephs DH, Ross PJ.
    Br J Hosp Med (Lond); 2010 Aug 15; 71(8):451-6. PubMed ID: 20852487
    [Abstract] [Full Text] [Related]

  • 12. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
    Vitale A, Lombardi G, Ramirez Morales R, Cillo U.
    Dig Liver Dis; 2012 May 15; 44(5):361-2. PubMed ID: 22424640
    [No Abstract] [Full Text] [Related]

  • 13. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
    Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU.
    Tumori; 2011 May 15; 97(4):436-41. PubMed ID: 21989430
    [Abstract] [Full Text] [Related]

  • 14. TACE with or without systemic therapy?
    Dufour JF.
    J Hepatol; 2012 Jun 15; 56(6):1224-5. PubMed ID: 22402292
    [No Abstract] [Full Text] [Related]

  • 15. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P.
    BMC Cancer; 2008 Nov 26; 8():349. PubMed ID: 19036146
    [Abstract] [Full Text] [Related]

  • 16. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G.
    Future Oncol; 2015 Nov 26; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract] [Full Text] [Related]

  • 17. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
    Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP, Fisher RA.
    Transplantation; 2014 Jul 15; 98(1):100-6. PubMed ID: 24503764
    [Abstract] [Full Text] [Related]

  • 18. Management of hepatocellular carcinoma with portal vein thrombosis.
    Quirk M, Kim YH, Saab S, Lee EW.
    World J Gastroenterol; 2015 Mar 28; 21(12):3462-71. PubMed ID: 25834310
    [Abstract] [Full Text] [Related]

  • 19. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
    Zhao JD, Liu J, Ren ZG, Gu K, Zhou ZH, Li WT, Chen Z, Xu ZY, Liu LM, Jiang GL.
    Radiat Oncol; 2010 Feb 12; 5():12. PubMed ID: 20149262
    [Abstract] [Full Text] [Related]

  • 20. Treating hepatocellular carcinoma without liver transplantation.
    Gogia S, Befeler AS.
    Curr Gastroenterol Rep; 2009 Feb 12; 11(1):69-75. PubMed ID: 19166662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.